RxDoctor Payments Data

Michael Sperling, MD

Internal Medicine · Galloway, NJNPI 1518222108

Payments from drug & device makers

$506in general payments, 2019–2025

Across 28 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$107
  • Novo Nordisk$84
  • Abbott$44
  • Boehringer Ingelheim$42
  • AstraZeneca$36
  • AbbVie$35
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$506100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$506 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$247,292
Medicare patients
539
Services billed
2,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$80,689
EliquisApixaban60$77,588
RybelsusSemaglutide31$68,763
XareltoRivaroxaban46$48,583
JardianceEmpagliflozin43$47,301
JanuviaSitagliptin Phosphate29$43,925
MounjaroTirzepatide25$29,121
FarxigaDapagliflozin Propanediol32$26,237
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl87$16,644
LinzessLinaclotide15$13,328
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,815
Tresiba Flextouch U-100Insulin Degludec16$9,116
Rosuvastatin Calcium340$8,375
Dexlansoprazole DrDexlansoprazole15$6,821
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$5,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$84$149,45385 claims
PfizerEliquis, Paxlovid$16$80,44785 claims
Boehringer IngelheimJardiance$42$47,30143 claims
AstraZenecaFarxiga, Symbicort$36$28,98444 claims
AbbVieLinzess, Creon, Synthroid$35$22,506107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Galloway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →